Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the treatment
of choice for the prevention of thrombotic events after percutaneous coronary intervention …

To the Editor: Prolonged dual antiplatelet therapy (DAPT) with the P2Y12 inhibitor on top of
aspirin is associated with increased bleeding risk. 1, 2 Therefore, stepwise DAPT de …

Background Dual-antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is
the mainstay regimen for acute coronary syndrome (ACS) patients after percutaneous …

Dual antiplatelet therapy (DAPT) with acetylsalicylic acid and a P2Y12 inhibitor is an
established therapy for a broad spectrum of patients with cardiovascular disease. The …

Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor significantly reduces the
risk of major adverse cardiovascular events (MACE) after myocardial infarction (MI), a …

Patients with atrial fibrillation (AF) are at an increased risk for thrombosis, and anticoagulant
therapy, preferably with a direct oral anticoagulant (DOAC) for most patients, is indicated for …

Purpose of review The optimal duration of dual antiplatelet therapy (DAPT) has been a topic
of considerable interest in recent years, as the risk of stent thrombosis has decreased with …

In this real-world, retrospective cohort study of 9753 patients in Japan prescribed dual
antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI), we …

Background: Dual antiplatelet therapy (DAPT) helps prevent ischemic events after coronary
stenting but comes with an increased risk of bleeding. Several risk scores have been …

This review is a summary of the European Society of Cardiology (ESC) guidelines focused
on dual antiplatelet therapy in patients after percutaneous coronary interventions (PCI) …